Comparative Study
. 2021 Jul;13(7):1256-1269.
doi: 10.1002/dta.3016. Epub 2021 Feb 22.
Affiliations
PMID: 33587816 DOI: 10.1002/dta.3016
Comparative Study
Detection of LongR3 -IGF-I, Des(1-3)-IGF-I, and R3 -IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes
Cynthia Mongongu et al. Drug Test Anal. 2021 Jul.
Abstract
Insulin-like growth factor-I (IGF-I) and its analogs LongR3 -IGF-I, Des(1-3)-IGF-I, and R3 -IGF-I are prohibited substances in sport. Although they were never approved for use in humans, they are readily available as black market products for bodybuilding and can be used to enhance physical performance. This study's aims were to validate a fast and sensitive detection method for IGF-I analogs and to evaluate their detectability after intramuscular administration in rats. The sample preparation consisted of an immunopurification on MSIATM microcolumns using a polyclonal anti-human-IGF-I antibody. The target substances were then directly analyzed by nano-liquid chromatography coupled with high-resolution mass spectrometry. Abundant signs of lower quality, oxidized peptide forms were found in black market products, justifying the need to monitor at least both the native and mono-oxidized forms. The analytical performance of this method (linearity, carry over, detection limits, precision, specificity, recovery, and matrix effect) was studied by spiking the analogs into human serum. Following a single intramuscular administration (100 μg/kg) in rats, detection was evaluated up to 36 h after injection. While unchanged Des(1-3)-IGF-I and R3 -IGF-I were detected until 24 h after administration, LongR3 -IGF-I disappeared rapidly after 4 h. Des(1)-LongR3 -IGF-I, a new N-terminal Long-R3 -IGF-I degradation product, was detected in addition to Des(1-10)-LongR3 -IGF-I and Des(1-11)-LongR3- IGF-I: the latter was detected up to 16 h. The same products were found after in vitro incubation of the analogs in human whole blood, suggesting that observations in rats may be extrapolated to humans and that the validated method may be applicable to antidoping testing.
Keywords: IGF-I analogs; MSIA; administration in rat; detection; high resolution mass spectrometry.
© 2021 John Wiley & Sons, Ltd.
PubMed Disclaimer
References
REFERENCES
Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem. 1978;253(8):2769-2776.
Hokama JY, Streeper RS, Henriksen EJ. Voluntary exercise training enhances glucose transport in muscle stimulated by insulin-like growth factor I. J Appl Physiol. 1997;82(2):508-512. https://doi.org/10.1152/jappl.1997.82.2.508
Velloso C. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. 2008;154(3):557-568. https://doi.org/10.1038/bjp.2008.153
Duan C, Ren H, Gao S. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins: roles in skeletal muscle growth and differentiation. Gen Comp Endocrinol. 2010;167(3):344-351. https://doi.org/10.1016/j.ygcen.2010.04.009
Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol. 1989;121(6):753-758. https://doi.org/10.1530/acta.0.1210753